0
Description
Bortezomib is the first of its class to be approved for clinical use. It is a 26S proteosome inhibitor (26S proteosome is the principal regulator of the intracellular protein degradation that helps in cell proliferation and survival regulation).
Indications:
- For the treatment of patients with multiple myeloma
- For the treatment of patients with mantle cell lymphoma who have received at least 1 prior therapy
|
Generic Name |
Strength |
Standard |
Type |
Packing |
Pack Size |
|
Bortezomib |
2 mg / 3.5mg |
USP |
INJ |
Vial |
1 Vial |
Reviews
There are no reviews yet.